Waters Corporation Unveils Charge Detection Mass Spectrometry Technology

Waters Corporation has launched the Xevo Charge Detection Mass Spectrometer (CDMS), a new technology designed to enhance the development of next-generation biotherapeutics. The tool allows for precise mass detection of large, heterogeneous biomolecules, addressing key analytical challenges in the rapidly evolving field of cell and gene therapies.

The Xevo CDMS enables accurate analysis of protein complexes, nucleic acids, and viral vectors. It distinguishes between various viral capsids quickly, using significantly less sample volume than conventional methods. This capability not only speeds up development but also enhances the safety and efficacy of advanced therapies.

The system is powered by the GxP-ready waters_connect™ Software and is commercially available. Waters’ investment in this technology reflects the company’s commitment to advancing bioanalytical characterization, aiding the development of life-changing therapies.